News Article | May 5, 2017
Global Animal Pharmaceutical market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including Zoetis Merck Merial Elanco Bayer Animal Health Boehringer Ingelheim Vetmedica Virbac Ceva Sante Animale Vétoquinol Jurox MSD Animal Health Australia PARNELL CAHIC Ringpu Biology Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Animal Pharmaceutical in these regions, from 2012 to 2022 (forecast), covering North America Europe China Japan Southeast Asia India On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into Vaccine Veterinary Drugs Other On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Animal Pharmaceutical for each application, including Companion Animal Poultry Other Global Animal Pharmaceutical Market Research Report 2017 1 Animal Pharmaceutical Market Overview 1.1 Product Overview and Scope of Animal Pharmaceutical 1.2 Animal Pharmaceutical Segment by Type (Product Category) 1.2.1 Global Animal Pharmaceutical Production and CAGR (%) Comparison by Type (Product Category) (2012-2022) 1.2.2 Global Animal Pharmaceutical Production Market Share by Type (Product Category) in 2016 1.2.3 Vaccine 1.2.4 Veterinary Drugs 1.2.5 Other 1.3 Global Animal Pharmaceutical Segment by Application 1.3.1 Animal Pharmaceutical Consumption (Sales) Comparison by Application (2012-2022) 1.3.2 Companion Animal 1.3.3 Poultry 1.3.4 Other 1.4 Global Animal Pharmaceutical Market by Region (2012-2022) 1.4.1 Global Animal Pharmaceutical Market Size (Value) and CAGR (%) Comparison by Region (2012-2022) 1.4.2 North America Status and Prospect (2012-2022) 1.4.3 Europe Status and Prospect (2012-2022) 1.4.4 China Status and Prospect (2012-2022) 1.4.5 Japan Status and Prospect (2012-2022) 1.4.6 Southeast Asia Status and Prospect (2012-2022) 1.4.7 India Status and Prospect (2012-2022) 1.5 Global Market Size (Value) of Animal Pharmaceutical (2012-2022) 1.5.1 Global Animal Pharmaceutical Revenue Status and Outlook (2012-2022) 1.5.2 Global Animal Pharmaceutical Capacity, Production Status and Outlook (2012-2022) 7 Global Animal Pharmaceutical Manufacturers Profiles/Analysis 7.1 Zoetis 7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.1.2 Animal Pharmaceutical Product Category, Application and Specification 184.108.40.206 Product A 220.127.116.11 Product B 7.1.3 Zoetis Animal Pharmaceutical Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.1.4 Main Business/Business Overview 7.2 Merck 7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.2.2 Animal Pharmaceutical Product Category, Application and Specification 18.104.22.168 Product A 22.214.171.124 Product B 7.2.3 Merck Animal Pharmaceutical Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.2.4 Main Business/Business Overview 7.3 Merial 7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.3.2 Animal Pharmaceutical Product Category, Application and Specification 126.96.36.199 Product A 188.8.131.52 Product B 7.3.3 Merial Animal Pharmaceutical Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.3.4 Main Business/Business Overview 7.4 Elanco 7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.4.2 Animal Pharmaceutical Product Category, Application and Specification 184.108.40.206 Product A 220.127.116.11 Product B 7.4.3 Elanco Animal Pharmaceutical Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.4.4 Main Business/Business Overview 7.5 Bayer Animal Health 7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.5.2 Animal Pharmaceutical Product Category, Application and Specification 18.104.22.168 Product A 22.214.171.124 Product B 7.5.3 Bayer Animal Health Animal Pharmaceutical Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.5.4 Main Business/Business Overview 7.6 Boehringer Ingelheim Vetmedica 7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.6.2 Animal Pharmaceutical Product Category, Application and Specification 126.96.36.199 Product A 188.8.131.52 Product B 7.6.3 Boehringer Ingelheim Vetmedica Animal Pharmaceutical Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.6.4 Main Business/Business Overview 7.7 Virbac 7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.7.2 Animal Pharmaceutical Product Category, Application and Specification 184.108.40.206 Product A 220.127.116.11 Product B 7.7.3 Virbac Animal Pharmaceutical Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.7.4 Main Business/Business Overview 7.8 Ceva Sante Animale 7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.8.2 Animal Pharmaceutical Product Category, Application and Specification 18.104.22.168 Product A 22.214.171.124 Product B 7.8.3 Ceva Sante Animale Animal Pharmaceutical Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.8.4 Main Business/Business Overview 7.9 Vétoquinol 7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.9.2 Animal Pharmaceutical Product Category, Application and Specification 126.96.36.199 Product A 188.8.131.52 Product B 7.9.3 Vétoquinol Animal Pharmaceutical Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.9.4 Main Business/Business Overview 7.10 Jurox 7.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.10.2 Animal Pharmaceutical Product Category, Application and Specification 184.108.40.206 Product A 220.127.116.11 Product B 7.10.3 Jurox Animal Pharmaceutical Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.10.4 Main Business/Business Overview 7.11 MSD Animal Health Australia 7.12 PARNELL 7.13 CAHIC 7.14 Ringpu Biology For more information, please visit https://www.wiseguyreports.com/sample-request/903489-global-animal-pharmaceutical-market-research-report-2017
News Article | April 21, 2017
Sarasota, FL, April 21, 2017 (GLOBE NEWSWIRE) -- Zion Market Research, the market research group announced the analysis report titled "Veterinary Vaccine Market by Application (Livestock Vaccines and Companion Vaccines), by Technology Types (Attenuated Vaccines, DNA Vaccines, Inactivated Vaccines, Toxoid Vaccines and Recombinant Vaccines) - Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021". The study concludes that the global veterinary vaccine market is expected to grow at a CAGR of 9.3% between 2016 and 2021. The market revenue of $12.10 billion in 2015 is expected to grow up to $20.60 billion by 2021. Vaccination is one of the most used applications of modern biotechnology to prevent chronic bacterial, viral and protozoal diseases. Veterinary vaccines are eco-friendly and used to increase animal welfare by preventing the death of animals, loss of dairy products and monetary loss of owners. Recently highly effective third generation vaccine against rabies virus has been developed with the help of recombinant technology. With the use of the vaccine, we can avoid the problem of antibiotic and drug resistance by the microorganism. Browse through 10 Market Tables and 39 Figures spread through 110 Pages and in-depth TOC on “Global Veterinary Vaccine Market: By Product, Type, Technology, Regions, Poultry, Diseases, Size, Share, Industry Trends, Segments, and Forecast 2015-2021”. Major factors responsible for the growth of veterinary vaccines market include increasing pet ownership, increasing awareness for food security and increasing investment by various government agencies. Increased veterinary research institutions and colleges are also adding value to veterinary vaccines market. However, rising maintenance cost of vaccine storage and prevalence of chronic disease of animals with continuous economic slowdown are hindering the growth of the market. Increasing demand for milk, eggs, meat & animal protein and investment by the government would represent the massive opportunity in future. On the basis of product type, the market of veterinary vaccines is bifurcated into livestock vaccines and companion vaccines. Livestock vaccines account the larger market share of more than 62% and companion vaccines accounts for around 38% share of global veterinary vaccine market. Livestock vaccines segment is classified into poultry, porcine and aquaculture vaccine type. The porcine vaccine is largest sub-segment with more than 30% share of global livestock market and it is expected to remain dominant during the forecast period. Companion vaccine is segmented into equine, canine and feline. Among these three segments, canine segments are the fastest growing segment with approximately 6% growth rate. Browse the full "Veterinary Vaccine Market by Application (Livestock Vaccines and Companion Vaccines), by Technology Types (Attenuated Vaccines, DNA Vaccines, Inactivated Vaccines, Toxoid Vaccines and Recombinant Vaccines) - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2015 – 2021" report at https://www.zionmarketresearch.com/report/veterinary-vaccine-market On the basis of technology type, the veterinary vaccines market is classified into attenuated vaccines, DNA Vaccines, inactivated vaccines, toxoid vaccines, and recombinant vaccines. With noticeable share, DNA, and attenuated vaccine segments were accounted highest growth for veterinary vaccine market in 2015. The veterinary vaccine market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. As a result of increasing demand for livestock veterinary vaccines, North America and Europe has the strong hold on veterinary vaccine market with more than 68% share. In North America, the U.S. and Canada are two major markets, while the U.S. market is expected to remain dominant with nearly 38% share in forecast period due to increasing pet ownership and growing demand for dairy products. Asia-Pacific is expected to show noticeable growth in forecast period as a result of strong demand from China and India. Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/veterinary-vaccine-market Key operating players for the veterinary vaccines market are Heska Corporation, Zoetis Inc., Ceva Santé Animale Inc., Merck Animal Health, Sanofi (Merial Animal Health), Boehringer Ingelheim GmbH, Eli Lilly and Company (Elanco Animal Health), Virbac, Bayer AG, and Bimeda. Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
News Article | April 28, 2017
The annual report of the fiscal year ending at December 31, 2016 of Virbac is available: · On our website : www.virbac.com under the section Investors - Financial reports - 2016, · Or on request, under legal and regulatory conditions.
Virbac Sa | Date: 2014-11-20
The invention relates to a topical veterinary composition for animals. It is characterized in that it comprises, in a physiologically acceptable medium, extracts of boldo Peumus boldus and extracts of meadowsweet Spiraea ulmaria. The invention applies in particular to preventing or treating or to assisting with the control of microbial infections.
Virbac Sa | Date: 2016-01-08
The invention relates to a packaging comprising: a rigid shell that can be deformed by having a user apply pressure, said shell forming a storage space (1) containing a liquid or pasty substance; a breakage area (6) for releasing an applicator (3) for ejecting the liquid or pasty substance from said packaging; and a gripping area (5) including an escape path (7) for said liquid or pasty substance, the escape path being naturally closed when the user applies no pressure such that the liquid or pasty substance is prevented from being discharged after opening the packaging
Virbac Sa | Date: 2016-01-08
The invention relates to a composition comprising revivable dehydrated micro-organisms. The invention is characterised in that it further comprises particles at least 50% of which have a mean diameter greater than 250 m. The invention is applicable, in particular, to human or veterinary pharmaceuticals, to dietetics or to food products.
Virbac Sa | Date: 2012-11-08
The invention relates to a product for oral administration intended for a pet, comprising extracts of punica granatum (pomegranate). The invention is characterised in that the invention further comprises at least two additional antioxidant compounds chosen from: soya isoflavone extracts; L-carnitine; and taurine.
Virbac Sa | Date: 2011-05-09
The invention relates to a composition for topical application as well as the use of such a composition. The invention is characterised in that it comprises at least one first and one second mono- or oligosaccharide, each of said first and second mono- or oligosaccharides being capable of limiting the adhesion of microorganisms on the skin of warm-blooded animals with coats.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SFS-01b-2014 | Award Amount: 10.52M | Year: 2015
SAPHIR aims to develop vaccine strategies effective against endemic pathogens responsible for high economic losses in livestock in order to strengthen the profitability of food animal systems, improve animal welfare and reduce xenobiotic usage in farming with a One Health perspective. SAPHIR will bring novel vaccine strategies to the market i) at short term, with several promising vaccines brought to demonstration (RTL6), ii) at long term, with cutting edge strategies brought at proof of concept (RTL3) and iii) in line with socio-economic requirements. SAPHIR has selected two representative pathogens of pigs (Porcine Reproductive and Respiratory Syndrome Virus and Mycoplasma hyopneumoniae), chickens (Eimeria and Clostridium perfringens) and cattle (Bovine Respiratory Syncytial Virus, Mycoplasma bovis) to develop generic vaccine approaches applicable to other pathogens. SAPHIR will issue i) knowledge of immune mechanisms of protection, ii) affordable, safe and multivalent vaccines with DIVA properties, iii) efficient adjuvants targeting dendritic cells, optimal formulations, new mucosal and skin delivery systems, a new generation of DNA vectors and viral replicon platforms for fostering an earlier and longer duration of immunity including the perinatal period, and iv) basal biomarkers of individual immuno-competence for future breeding strategies. The SAPHIR dissemination and training programme includes creation of an integrated health management website, launch of a Global Alliance for Veterinary Vaccines and organization of workshops directed at food animal system stakeholders. This will ensure optimal research translation of SAPHIR outputs to market and field applications. SAPHIR brings together interdisciplinary expertise from fourteen academic institutes including a Chinese partner, five SMEs and two pharmaceutical companies.
RAPSODI - PRe-clinicAl studies of a PSA-based human vaccine candidate targeting visceral, cutaneOus and mucocutaneous Leishmaniasis and Development of the associated procedures for further clinical trials
Agency: European Commission | Branch: FP7 | Program: CP-SICA | Phase: HEALTH-2007-2.3.4-2 | Award Amount: 4.00M | Year: 2009
The global aim of RAPSODI is : to develop a human vaccine candidate against most or all Leishmania species that cause the most severe leishmaniasis in the world. An unique vaccinal solution will thus be provided to protect against the various clinical phenotypes (namely visceral, cutaneous and mucocutaneaous leishmaniasis, VL, CL and ML respectively). to establish all the associated procedures required for the subsequent clinical trials, such as the selection of the appropriate patients and assessment of vaccine efficiency. For that purpose, an international consortium constituted of countries from endemic areas (India, Peru, Tunisia, Spain and France) and embracing multi-disciplinary approaches has been set-up. Based on successful results on VL dogs, the best VL animal model to date, RAPSODI will propose a second generation human-compatible vaccine candidate and confirm its activity in pre-clinical studies. As the chosen antigen is common to most, if not all, Leishmania species, an ambitious universal immunoprotective response is being sought. RAPSODI will also address the question of population selection in order to ascertain relevant and meaningful clinical trials and vaccination campaigns. Indeed, resistant individuals, when involved in either vaccinated or placebo groups, represent important bias to the analysis of the results. RAPSODI will investigate further the parasitological, immunological and genetic features of such clinical status, and will subsequently apply the generated knowledge to the development of assays and field tests, which represent stand-alone results. The package (vaccine candidate \ diagnostic/prognostic tools) proposed by RAPSODI represents a global solution, and as such is believed to have a real impact on the worldwide leishmaniasis problem.